General information only. Not medical advice. Discuss any testing with your specialist oncology team. Advertising-compliant summary aims to present balanced, referenced information and includes risks and limitations, consistent with AHPRA guidance on evidence-based health information. Ahpra

What is CTC / RGCC testing?

Circulating tumour cell (CTC) tests analyse cancer cells found in a blood sample (“liquid biopsy”). RGCC-branded assays are one type of CTC analysis that may also report ex-vivo drug sensitivity results. CTCs are being studied for prognosis and monitoring in many cancers, but the degree of proven clinical utility varies by context. Nature+1

Potential benefits (what current evidence suggests)

Minimally invasive monitoring: Blood draws can be repeated to track disease burden and biology over time. Nature+1
Prognostic value in some settings: Higher CTC counts are often associated with poorer outcomes; this is best established in metastatic disease.
Research pathways for therapy insights: Early-stage studies show that drug testing on patient-derived CTCs or CTC-organoids can sometimes mirror responses seen in metastatic tumours, but these methods remain investigational. ScienceDirect+2EJ Cancer+2

Important limitations and risks

Not a substitute for guideline-directed care: Major oncology guidelines have long concluded that chemosensitivity/resistance assays (testing drugs on tumour cells outside the body) lack sufficient evidence to guide routine treatment decisions. This caution extends to similar ex-vivo CTC drug panels. ASCO Publications+2Anthem+2
Variable analytical methods: CTC capture and analysis technologies differ and may yield different results; standardisation is evolving. cell.com
Uncertain impact on outcomes: For most cancers, using CTC/RGCC results to pick treatments has not been proven to improve survival or quality of life in randomised trials. ASCO Publications
Potential for false reassurance or unnecessary treatment changes: Over-interpreting exploratory results can delay evidence-based therapy. ASCO Publications
Cost and access: Tests may be costly and not publicly funded; turnaround times and reproducibility can vary. (General consideration; check with your provider.)
Regulatory context (Australia): Laboratory-developed tests and advanced biological techniques operate within the TGA framework and broader clinical-trial governance; claims about benefits in advertising require high-quality, directly relevant evidence. Therapeutic Goods Administration (TGA)+2Therapeutic Goods Administration (TGA)+2

What Australian regulators and guideline bodies emphasise

Evidence standards in health advertising: AHPRA requires that information provided to the public is accurate, balanced and supported by acceptable evidence; testimonials and guarantees of benefit are not permitted. Ahpra+1
Cancer care should align with national guidelines: Clinical decisions should reference Australian clinical practice guidelines where available; novel tests are ideally used within research or after multidisciplinary review. Cancer Council Australia+1

Practical takeaways for patients

If you are considering RGCC/CTC testing, discuss:
- Purpose: monitoring vs. directing therapy.
- How results would (or would not) change your current plan in line with guidelines.
- Costs/limitations and whether testing is part of a research protocol.
- Alternative, guideline-endorsed tests (e.g., tumour sequencing, ctDNA where indicated). cell.com

Key references (selected)

ASCO Technology Assessment Update: Chemotherapy Sensitivity & Resistance Assays—insufficient evidence for routine use. ASCO Publications
Reviews on CTC biology, detection limits, and emerging applications. cell.com+2Nature+2
Early research showing ex-vivo CTC drug testing concordance with metastatic response (investigational). ScienceDirect+2EJ Cancer+2
Australian regulatory/advertising context (TGA frameworks; AHPRA advertising guidance). Therapeutic Goods Administration (TGA)+2Therapeutic Goods Administration (TGA)+2